Alimera Sciences, Inc. (NASDAQ:ALIM) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued on Friday.

According to Zacks, “Alimera Sciences, Inc., based in Alpharetta, Georgia, is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company is presently focused on diseases affecting the back of the eye, or retina because it believes these diseases are not well treated with current therapies and represent a significant market opportunity. Its product candidate Iluvien(R) is an intravitreal insert containing fluocinolone acetonide, a non-proprietary corticosteroid with demonstrated efficacy in the treatment of ocular disease. Iluvien is in development for the treatment of diabetic macular edema (DME). DME is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness. “

Several other research firms also recently weighed in on ALIM. ValuEngine upgraded Alimera Sciences from a “sell” rating to a “hold” rating in a report on Thursday, July 13th. HC Wainwright restated a “buy” rating and issued a $5.00 price objective on shares of Alimera Sciences in a report on Wednesday, August 30th. Finally, Cowen and Company set a $3.00 price objective on Alimera Sciences and gave the company a “buy” rating in a report on Tuesday, July 25th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average target price of $3.38.

Alimera Sciences (NASDAQ ALIM) opened at 1.39 on Friday. The company has a 50 day moving average of $1.44 and a 200 day moving average of $1.43. Alimera Sciences has a 52 week low of $1.03 and a 52 week high of $1.72. The company’s market capitalization is $95.98 million.

Alimera Sciences (NASDAQ:ALIM) last released its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, beating the consensus estimate of ($0.05) by $0.01. The firm had revenue of $10.40 million during the quarter, compared to the consensus estimate of $10.20 million. The business’s revenue was up 8.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.17) earnings per share. On average, equities analysts forecast that Alimera Sciences will post ($0.21) EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Alimera Sciences, Inc. (ALIM) Stock Rating Upgraded by Zacks Investment Research” was posted by Watch List News and is owned by of Watch List News. If you are reading this news story on another website, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright law. The legal version of this news story can be read at https://www.watchlistnews.com/alimera-sciences-inc-alim-stock-rating-upgraded-by-zacks-investment-research/1551794.html.

Institutional investors have recently made changes to their positions in the business. Kennedy Capital Management Inc. bought a new position in Alimera Sciences in the first quarter worth about $467,000. JW Asset Management LLC raised its holdings in Alimera Sciences by 15.6% in the second quarter. JW Asset Management LLC now owns 966,000 shares of the biopharmaceutical company’s stock worth $1,343,000 after purchasing an additional 130,000 shares in the last quarter. KCG Holdings Inc. raised its holdings in Alimera Sciences by 127.0% in the first quarter. KCG Holdings Inc. now owns 78,604 shares of the biopharmaceutical company’s stock worth $110,000 after purchasing an additional 43,977 shares in the last quarter. Finally, PNC Financial Services Group Inc. raised its holdings in Alimera Sciences by 24.3% in the second quarter. PNC Financial Services Group Inc. now owns 180,300 shares of the biopharmaceutical company’s stock worth $251,000 after purchasing an additional 35,200 shares in the last quarter. Institutional investors and hedge funds own 37.20% of the company’s stock.

Alimera Sciences Company Profile

Alimera Sciences, Inc (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina.

Receive News & Ratings for Alimera Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.